Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 3/20 | 0.82 |
| ▸ | CCR1 | P32246 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2273635 | 0.92 | ELANE (0.81) | ELANECCR1MEN1KMT2ANPSR1 | |
| SCHEMBL28777146 | 0.90 | ELANE (0.67) | ELANECCR1MEN1KMT2AKDM4E | |
| SCHEMBL2273394 | 0.90 | ELANE (1.00) | ELANECCR1MEN1KMT2A | |
| SCHEMBL3150989 | 0.86 | ELANE (0.62) | ELANECCR1MEN1KMT2AKDM4E | |
| SCHEMBL27749321 | 0.82 | ELANE (0.66) | ELANECCR1MEN1KMT2ANPSR1 | |
| SCHEMBL8219783 | 0.82 | ELANE (0.66) | ELANECCR1MEN1KMT2AKDM4E | |
| SCHEMBL6882229 | 0.81 | ELANE (0.65) | ELANECCR1MEN1KMT2AKDM4E | |
| SCHEMBL985971 | 0.80 | ELANE (0.83) | ELANEMEN1KMT2ANOTUM | |
| SCHEMBL17378390 | 0.80 | ELANE (0.83) | ELANEMEN1KMT2A | |
| SCHEMBL987063 | 0.80 | ELANE (0.82) | ELANECCR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998984-B2 | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | ASTRAZENECA AB (SE) | 2011-08-16 | — | — | US | claimed |
| EP-2018375-B1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | ASTRAZENECA AB (SE) | 2010-03-03 | — | — | EP | claimed |
| US-20090131486-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | claimed |
| US-7998984-B2 | 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial | ASTRAZENECA AB (SE) | 2011-08-16 | — | — | US | disclosed |
| EP-2018375-B1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL. | ASTRAZENECA AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| US-20090131486-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131486-A1 | 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL | SERPINB1, ELANE, SERPINB6 | ELANE 2/4885CCR1 346/4885MEN1 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.